Key Points
- Director Mika Nishimura sold 4,100 shares on March 12 at an average price of $13.83 for a total of $56,703, reducing her stake by 11.14% to 32,716 shares.
- SiBone shares opened at $13.05 and were down about 5.6%, trading near their one‑year low ($12.49) with a market cap of roughly $576 million and a negative P/E of -29.66.
- The company slightly beat quarterly EPS estimates (‑$0.04 vs. ‑$0.13) with revenue essentially in line, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $24.67.
SiBone (NASDAQ:SIBN - Get Free Report) Director Mika Nishimura sold 4,100 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $13.83, for a total transaction of $56,703.00. Following the completion of the sale, the director owned 32,716 shares in the company, valued at approximately $452,462.28. This trade represents a 11.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
SiBone Stock Down 5.6%
NASDAQ:SIBN opened at $13.05 on Friday. The company has a market capitalization of $576.42 million, a price-to-earnings ratio of -29.66 and a beta of 0.69. SiBone has a one year low of $12.49 and a one year high of $21.89. The stock has a 50-day simple moving average of $16.28 and a 200 day simple moving average of $16.72. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.21 and a current ratio of 8.55.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.09. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%.The firm had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. Sell-side analysts predict that SiBone will post -0.78 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms recently issued reports on SIBN. Truist Financial reissued a "buy" rating and set a $24.00 price target (up from $23.00) on shares of SiBone in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SiBone in a report on Monday, December 29th. Needham & Company LLC boosted their target price on shares of SiBone from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, December 16th. Morgan Stanley increased their target price on shares of SiBone from $20.00 to $23.00 and gave the stock an "overweight" rating in a report on Tuesday, December 2nd. Finally, Canaccord Genuity Group raised their price target on shares of SiBone from $26.00 to $27.00 and gave the stock a "buy" rating in a research report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, SiBone has a consensus rating of "Moderate Buy" and an average price target of $24.67.
Check Out Our Latest Stock Report on SIBN
Institutional Trading of SiBone
Institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company's stock worth $343,000 after purchasing an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in SiBone during the 1st quarter worth $225,000. Goldman Sachs Group Inc. grew its stake in SiBone by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company's stock worth $5,328,000 after buying an additional 83,919 shares during the last quarter. Jane Street Group LLC acquired a new stake in SiBone in the first quarter worth $1,818,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in SiBone in the second quarter valued at $1,403,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.
SiBone Company Profile
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
